Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Overview
Date Founded

1925

Headquarters

4-1-1 Dosho-machi,Chuo-Ku,Osaka 540-8645

Type of Company

Public

Employees (Worldwide)

47.5K

Industries

Pharmaceuticals
IT Consulting & Services
Hospitals & Patient Services
Medical Support Services
Chemicals
Biotechnology

Company Description

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Contact Data
Trying to get in touch with decision makers at Takeda Pharmaceutical Co., Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Director Chief Financial Officer

Corporate Officer & Global General Counsel

Chief Ethics & Compliance Officer

Chief Medical & Scientific Officer

Chief Human Resources Officer

General Manager, Health Innovation Park-Shonan

President, Europe & Canada Business Unit

President, US Business Unit & Global Portfolio Commercialization

President, Japan Pharma Business Unit

Board of Directors

External Director at Takeda Pharmaceuticals U.S.A., Inc.

Founder at Tomon Partners LLC

Managing Director at ARCH Venture Partners

Operating Partner at Clarus Ventures LLC

Senior Adviser at EW Healthcare Partners

Advisor at Mindmaze SA

Chief Executive Officer at Takeda Pharmaceutical Co., Ltd.

Director Chief Financial Officer at Takeda Pharmaceutical Co., Ltd.

Director at Toshiba Corp.

External Director at NEXON

Paths to Takeda Pharmaceutical Co., Ltd.
Potential Connections via
Relationship Science
You
Takeda Pharmaceutical Co., Ltd.
Owners & Shareholders
Details Hidden

NAM-J’s investment philosophy has core elements including: active management focusing on fundamental research; a team approach; and thorough risk/return assessment. They offer a broad range of equity strategies, including core, value, and growth. The investment approach of the core strategy combines a bottom-up, relative value approach with rigorous fundamental research on individual stocks and a top-down overlay. The investment process is designed to add value in all market conditions over a medium- to long-term horizon. For value, they use bottom-up approach without sector constraints where the quality of stock selection is paramount. The investment process is based on a combination of rigorous quantitative screening based on valuation factors with liquidity consideration and qualitative analysis on firms’ fundamentals. The growth strategy focuses on ROE level and sustainability and fundamental strength. In conducting NAM-J’s investment decisions, they utilize a broad spectrum of information, including financial publications, third-party research materials, annual reports, prospectuses, regulatory filings, company press releases, corporate rating services, inspections of corporate activities and meetings with management of various companies.

Details Hidden

DAM conducts in-house research and has a strong global research network. Their investment management philosophy is based on a mid-to-long-term perspective in which they try to identify hidden values which are not yet fully recognized in the market. The firm takes a balanced approach emphasizing both fundamental and quantitative analysis. DAM’s basic assumption is that the market is not fully efficient and they employ a coherent investment process through organizational support at each phase of their 'Plan', 'Do' and 'Review' policy. They pursue stable excess mid-to long-term returns through suitable risk control, which they separate from investment management to ensure that the risk control system adequately monitors their investment process. The firm’s research team analysts and portfolio managers discuss, evaluate and communicate market events and investment opinions, seeking to maximize portfolio performance. Company visits are important components of their bottom-up research process and are a primary source for their fundamental analysis.

Details Hidden

MUFJ-AM is an active, value-oriented manager which follows a variety of investment styles, depending on portfolios. The firm invests globally across asset classes with a strong focus on Japan, targeting undervalued companies. They also invest marginally in Europe particularly in the UK and in Asia. Their investment philosophy emphasizes fundamental research, the expertise of portfolio managers and a stringent risk control process. MUFJ-AM focuses on long-term risk-adjusted returns and use momentum analysis as a determinant for investment decisions.

Recent Transactions
Details Hidden

Celltrion, Inc. purchases Takeda Pharmaceuticals (Asia Pacific) Pte Ltd. from Takeda Pharmaceutical Co., Ltd.

Details Hidden

Orifarm Group A/s purchases Takeda Pharmaceutical Co. Ltd. /Europe OTC Portfolio from Takeda Pharmaceutical Co., Ltd.

Details Hidden

Pharma Strategy Partners GmbH, Acino Pharma AG purchase Takeda Pharmaceuticals Co. Ltd. /Primary Care Portfolio Bus from Takeda Pharmaceutical Co., Ltd.

Transaction Advisors
Investment Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Pharmaceuticals International GmbH from Credit Suisse Group AG, aPriori Capital Partners LP, Coller Capital Ltd., Nordic Capital V Ltd., Avista Capital Partners, Nordic Capital VI Ltd., Coller International Partners IV LP, Coller International Partners V LP, Nordic Capital Ltd.

Legal Advisor

Advised onNovartis AG purchases Takeda Pharmaceutical Co. Ltd. /Xiidra Business from Takeda Pharmaceutical Co., Ltd.

Legal Advisor

Advised onHypera SA purchases from Takeda Pharmaceutical Co., Ltd.

Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Oncology Co.

Legal Advisor

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Pharmaceuticals International GmbH from Credit Suisse Group AG, aPriori Capital Partners LP, Coller Capital Ltd., Nordic Capital V Ltd., Avista Capital Partners, Nordic Capital VI Ltd., Coller International Partners IV LP, Coller International Partners V LP, Nordic Capital Ltd.

Attorney

Advised onTakeda Pharmaceutical Co., Ltd. purchases Takeda Oncology Co.

Advisors & Consultants
Legal Advisor

Partner at Hogan & Lovells LLP

Advisor

Co-Founder at Outpost Medicine LLC

Legal Advisor

Partner at BDT Capital Partners LLC

Clients

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Key Stats and Financials As of 2020
Market Capitalization
$54B
Total Enterprise Value
$92.7B
Earnings Per Share
$0.26
EBITDAMargin
26.93%
Enterprise Value / Sales
3.04x
Enterprise Value EBITDAOperating
11.29x
TEVNet Income
226.26x
Debt TEV
0.55x
Three Year Compounded Annual Growth Rate Of Revenue
23.86%
Revenue
$30.5B
Net Profit
$410M
EBITDA
$8.21B
Total Debt
$50.6B
Total Equity
$43.8B
Non-Profit Donations & Grants
Investments
Details Hidden

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Details Hidden

SCOHIA PHARMA, Inc. is a Japanese company located in Fujisawa that engages in research and development on drugs for the treatment of chronic diseases. It was founded in 2017.

Details Hidden

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

Investors
Details Hidden

Life Peer at United Kingdom House of Lords

Details Hidden

Hereditary Peer at United Kingdom House of Lords

Details Hidden

Co-Founder at Oak HC/FT Management Co. LLC

Suppliers
Alnylam Pharmaceuticals, Inc. Medical Support Services | Cambridge, Massachusetts

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Aska Pharmaceutical Co., Ltd. Retail: Drug Stores | Tokyo, Japan

ASKA Pharmaceutical Co., Ltd. engages in the manufacture, sale, import, and export of pharmaceuticals, veterinary medicine, quasi-drugs, food, and medical devices. It operates through the Pharmaceutical Business and Other segments. The Pharmaceutical Business segment manufactures and sells medical drugs. The Other segment includes veterinary drugs, clinical testing, and medical devices. The company was founded by Yasohachi Yamaguchi on June 16, 1920 and is headquartered in Tokyo, Japan.

H. Lundbeck A/S Pharmaceuticals | Valby, Denmark

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Takeda Pharmaceutical Co., Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Takeda Pharmaceutical Co., Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Takeda Pharmaceutical Co., Ltd..